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Long-term follow-up of a “donor” versus “no donor” comparison in multiple myeloma 
patients at first relapse after failing autologous transplantation 
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We report the long-term clinical outcomes of a retrospective multicentre study that enrolled 169 
multiple myeloma (MM) patients at first relapse after failing autologous stem cell transplantation 
(SCT). After HLA-typing at relapse, 79 patients with a suitable donor, 72 (91%) of whom 
eventually underwent salvage allogeneic SCT, were compared with 90 patients without a donor  
who were treated with multiple lines of salvage treatment with bortezomib and/or immune- 
modulating agents. At a median follow-up of 30 months (range 2-180) for all patients and 110 
months (range 38-180) for surviving patients, 7-year progression free survival (PFS) was 18% in 
the donor group and 0% in the no-donor group (hazard ratio [HR] 2.495; 95% CI, 1.770-3.517; 
p<0.0001). Seven-year overall survival (OS) was 31% in the donor group and 9% in the no-donor 
group (HR 1.835; 95% CI, 1.306-2.577; p<0.0001). By multivariate analysis, chemo-sensitivity to 
salvage treatments and presence of a suitable donor were significantly associated with better PFS 
and OS. The long term follow-up of this study confirms the significant PFS benefit and provides 
new evidence of an OS advantage for MM patients who have a suitable donor and undergo 
allogeneic SCT. Allogeneic SCT should be considered as a treatment option in young relapsed 








 These are the long-term results of a donor vs no donor comparison in multiple myeloma 
patients at first relapse after autologous stem cell transplantation (SCT). 
 
 A significant benefit of progression free survival and overall survival was shown in the 
donor group at a median follow-up of 110 months. 
 
 This study suggests that allogeneic SCT could be an option in young patients with high-risk 








Despite a tremendous expansion of the drug armamentarium for multiple myeloma (MM) in the 
past two decades, MM patients invariably relapse and mainly die of disease progression. Allogeneic 
hematopoietic stem cell transplantation (allo-SCT) from related and unrelated donors was mostly 
applied to young patients with relapsed MM in the early 2000’. Major limits of this approach were 
the high relapse rate, significant morbidity due to chronic GVHD and very low rates of long-term 
disease control, if any. These limitations led to a progressive reduction of the number of allo-SCT 
performed in relapsed MM patients in Europe (1). However, clinical results on allo-SCT in relapsed 
patients were biased by the retrospective nature of the analyses and the heterogeneity of patient 
cohorts including patients in different disease stages, with the predominance of heavily pre-treated 
patients. Moreover, most studies enrolled patients who had not been treated with “new drugs” or 
had incomplete data on salvage treatments (2-5). In 2011, we initially reported the clinical findings 
of a multicentre retrospective study (6) with an original design for the following points: a) all 
patients included were at first relapse after failing autologous stem cell transplantation (auto-SCT); 
b) patients received salvage treatment with “new drugs” 3) clinical outcomes between patients with 
and without a suitable HLA-matched donor were compared. Here, we present the long-term follow- 
up of the study showing a survival advantage for the transplanted patients. 
 
Patients and methods 
 
A multicentre retrospective study was conducted in 7 Haematology Centres between 2002 and 2008 
and included patients who relapsed after first-line auto-SCT and were then treated with salvage 
therapy based on bortezomib and/or immune-modulating agents (thalidomide and lenalidomide). 
The study was designed by an intention-to-treat analysis and included only those patients who 
underwent HLA typing immediately after the relapse. One-hundred sixty-nine patients were 
enrolled. Overall, a total of 79 patients (47%) had a suitable donor and 90 (53%) did not. Seventy- 
two of the 79 patients with a donor (91%) underwent allo-SCT while 7 (9%) did not undergo the 
planned allo-SCT because of disease progression or severe comorbidities (table 1). In comparison 
with our first report (6), 4 additional patients found a donor and underwent allo-SCT. Donors were 
HLA-identical sibling (no. 25) or HLA-matched or single class I allele/antigen mismatched 
unrelated donors (no. 47). Fifty-four out of 72 patients (76%) received peripheral blood stem cells. 
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All conditioning regimens were fludarabine-based, with the addition of 2 Gy total body irradiation 
(TBI) (no. 27) or melphalan (no. 28) or other alkylating agents (no. 17). Anti-thymocyte globulin 
(ATG) was administered in 24 out of 47 (51%) unrelated donors (table 2). MM response and acute 




The close-out date was December 2010 for the first analysis (6) and February 2017 for the present 
update. Patient status (alive/dead) was updated for all 169 patients while disease status 
(remission/progression) was collected for 162 as data were incomplete in 7 out of 169. Two 
analyses were performed: “donor” versus “no donor” group by intent-to-treat analysis; and patients 
who eventually completed the allo-SCT program versus those who received other treatments as by 
protocol. Non-relapse mortality (NRM), overall survival (OS), progression-free-survival  (PFS) 
were defined as previously published (6). Comparison between groups were performed using the t 
test or Chi test, as required. OS and PFS curves were compared using Cox proportional hazard 
models. Multivariate stepwise analyses included all variables found to be significant at P < .10 by 
univariate analysis. Retention in the stepwise model required the variable be significant at P < .05 




Patient median age at the time of auto-SCT was 57 years (range 31-73). Karyotype was evaluated  
at diagnosis by FISH analysis in 68 out of 169 patients (40%). Twenty-eight out of 68 (41%)  
carried either t (4:14), 17p deletion, or 13q deletion. Ninety-eight patients (58%) performed auto- 
SCT before 2004 and 110 (65%) underwent tandem auto-SCT. Median time to first relapse from 
auto-SCT was 16 months (range 2-88). Salvage treatments included thalidomide-based regimens in 
74 patients (44%), bortezomib-based in 55 patients (32%), lenalidomide-based in 27 patients (16%) 
and included other drugs in the remaining 13 patients (8%), without significant differences between 
the 2 groups. Median duration of salvage treatment was 5 months (range 1-55), response was 
observed in 100 patients (59%), 45 achieved complete remission (CR) or very good partial 
remission (VGPR) and 65 partial remission (PR). Clinical characteristics were well balanced 
between the “donor” versus the “no-donor groups” with the exception of younger median age and 
higher response rate to salvage treatment for the donor group (55 years versus 59, p=0.0001; 
CR+VGPR, PR and resistance rates of 38%, 43% and 19% versus vs 26%, 33%, 31%, p=0.039 
respectively) (table2). 
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Median follow-up after the beginning of salvage treatment was 30 months (range 2-180) in all 
patients and 110 months (range 38-180) in surviving patients. Seven-year PFS was 18% in the 
“donor” group and 0% in the “no-donor” group (hazard ratio [HR] 2.495; 95% CI, 1.770-3.517; 
p<0.0001). Seven-year OS was 31% in the “donor” group and 9% in the “no-donor group” (HR 
1.835; 95% CI, 1.306-2.577; p<0.0001). Significant variables (p< .10) which were associated with 
PFS by univariate proportional hazards model were absence of a suitable donor, high-risk 
karyotype, duration of salvage treatment and failure to achieve at least PR before allo-SCT. Those 
associated with OS were older age, absence of a suitable donor, high-risk karyotype and resistance 
to salvage treatment before allo-SCT. By multivariate analysis, resistance to salvage treatment and 
absence of a donor significantly reduced both PFS and OS (PFS: HR 2.243; 95% CI, 1.200-4.189; 
p=0.011; HR 2.311; 95% CI, 1.278-4.178; p=0.006, respectively. OS: HR 2.007; 95% CI, 1.098- 
3.668; p=0.024; HR 1.891; 95% CI, 1.087-3.289; p=0.024, respectively). 
 
A total of 72 out of 79 patients (91%) with a donor eventually underwent allo-SCT. Cumulative 
incidence of NRM at 5 years was 27%. Grade II-IV acute GVHD developed in 24 patients (33%) 
and chronic GVHD was seen in 43 out of 66 evaluable patients (65%). Chronic GVHD was graded 
(NIH criteria) as follows: limited in 20 patients, moderate and severe in 16 and 7 patients, 
respectively. Estimated 7-year PFS and OS were 20% and 35%, respectively. At last follow-up, 12 
patients (17%) are alive and in persistent clinical remission, 4 (33%) of them with limited chronic 
GVHD but off immunosuppression and good quality of life. Six other patients are long-term 
survivors though relapse occurred at a median of 77 months (range 8-129) and were rescued with 
new drugs with the addition of donor lymphocyte infusions in 2 patients. 
 
By univariate analysis, failure to obtain at least PR before allo-SCT was the only significant 
variable associated with worse PFS (HR 2.976; 95% CI, 1.304-6.792; p=0.010), while bone marrow 
as stem cell source was associated with worse OS (HR 2.470; 95% CI, 1.156-5.262; p=0.010). 







The first analysis of the present study was performed at a median follow-up of 29 months. 
Though the donor group showed a significantly longer PFS as compared with the no donor group, 
2-year OS were similar (54% vs 53%, respectively). In the current updated analysis, at a median 
follow-up of 110 months for surviving patients, not only PFS but also OS were significantly better 
in the donor group. Other studies previously suggested that a long follow-up might be necessary to 
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observe a potential survival advantage of allo-SCT over other treatments in MM, mainly due to a 
prolonged graft-vs.-myeloma (GvM) effect and/or a synergy with salvage treatments. The EBMT 
study (10) comparing outcomes between donor and no donor groups in newly diagnosed MM 
showed that a follow-up longer than 5 years was required to highlight the superior outcome of the 
donor group given that early NRM related to allo-SCT could initially cancel the effects of GvM. 
Moreover, the EBMT trial along with the GITMO study (10-12) reported a significantly longer OS 
from the time of first relapse in allo-SCT patients as compared with auto-SCT patients. These 
findings may mostly be due to a synergy between GvM and new drugs in long-term survivors after 
allo-SCT. In our study, rates of continuous complete remissions were low in both donor group and 
allo-SCT patients (18% and 20% at 7 years after allo-SCT, respectively) and PFS curves did not 
show a clear plateau indicating late MM relapses. Nonetheless, it is important to point out that these 
clinical outcomes were achieved with drugs and treatment strategies used longer than 10 years ago 
and mostly considered presently outdated. In fact, most patients underwent first-line auto-SCT 
before 2004; thus they could not benefit from bortezomib-based induction and maintenance after 
transplant. At that time, salvage treatment of first relapse was thalidomide-based for 44% of patients 
and lenalidomide-based in only 16% of patients and it was protracted for a short period (median 5 
months). Our study confirmed that the achievement of at least a partial response to second-line 
treatment was the most important factor influencing PFS and OS; therefore, it can hypothesized that 
novel combinations of drugs including second-generation proteosoma inhibitors or monoclonal 
antibodies could improve quality of response after salvage and outcome after subsequent allo-SCT 
(13). 
 
Some investigators suggest that the current role of allo-SCT should prospectively be 
evaluated at first relapse in young fit MM patients with high-risk clinical features, including early 
relapse, and/or poor prognosis cytogenetic abnormalities (14-16). In our analysis, we could not 
evaluate the impact of cytogenetics as data were incomplete in half of our patients mainly due to the 
fact that at the time of this study cytogenetic abnormalities were not routinely tested at all centers. 
Of note, time from auto-SCT to first relapse did not have a significant impact on clinical outcomes 
after allo-SCT, suggesting that GvM may overcome the unfavorable prognostic significance of  
early relapse. Most previous studies, that included reduced intensity conditioning and peripheral 
blood as stem cell source, reported significant mortality and morbidity due to chronic GVHD (17- 
18). In our case series overall and moderate-severe chronic GVHD rates were 65% and 32%, 
respectively, suggesting that this complication could contribute to increasing late NRM and 
impairing the survival benefit. However, the achievement of immunotolerance can be hypothesized 
in long-term survivors, since all our 12 surviving patients were off immunosuppression with good 
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quality of life though a persistent limited chronic GVHD in 4 of them. 
  
We conclude that the long term follow-up of the study confirms the significant PFS benefit and 
provides evidence of an OS advantage of RIC allo-SCT in relapsed MM patients who have a 
suitable donor, suggesting that allo-SCT could be an option in young patients with high-risk relapse 
after first- line treatment. However, allo-SCT allowed long-term MM control only in a small 
fraction of patients, indicating the need of achieving a deeper response before the procedure and 
administering consolidation and maintenance after transplant. The availability of new immune 
modulatory agents and monoclonal antibodies targeting both myeloma and immune cells could help 
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complete remission; VGPR: very good partial remission; PR: partial remission). 
 
Table 2. Characteristic of 72 allogeneic transplants (TBI : total body irradiation; SCT: stem cell 
transplantation ) 
 
Figure 1. Comparison of progression free survival (PFS) between donor and no-donor groups 
(p<0.0001) by intent-to-treat analysis. 
 
Figure 2. Comparison of overall survival (OS) between donor and no-donor groups (p<0.0001) by 
intent-to-treat analysis. 
Table  1. Clinical  characteristic  of  the  167 patients included in the study (SCT: stem cell 
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 Donor group No donor group p 
N° pts 79 90  















Time diagnosis-autoSCT, months 
median (range) 















Tandem auto-SCT 48/79 (60%) 62/90 (69%) 0.215 
Time auto-SCT-relapse, months 
median (range) 
16 (2-88) 16 (2-54) 0.668 


















Treatment duration , months 
median (range) 
5 (1-52) 5 (1-55) 0.278 





























N° pts 72 





HLA matched sibling 25 /72 (35%) 
Unrelated 47/72 (65%) 
Source  
Bone marrow 18/72 (24%) 
Peripheral blood 54/72 (76%) 
Conditioning regimen  
Fludarabine, melphalan ±thiotepa 28/72 (39%) 
Fludarabine + 2 Gy TBI ± melphalan 27/72 (37%) 
Fludarabine + other alkylating agents 17/72 (24%) 
Anti-thymoglobulin 24/72 (33%) 
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